Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839-852.
FDA. FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma. News release. February 5, 2021. Accessed February 5, 2021. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma#:~:text=FDA%20approves%20lisocabtagene%20maraleucel%20for%20relapsed%20or%20refractory%20large%20B%2Dcell%20lymphoma,-Share&text=On%20February%205%2C%202021%2C%20the,%2C%20Juno%20Therapeutics%2C%20Inc.).
Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38:3095-3106.
Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15:813-822.
KYMRIAH™ (tisagenlecleucel) [prescribing information]. Novartis Pharmaceutical Corporation. Approved 2017. Revised May 2018.
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31-42.
Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large b-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 202020;38:3119-3128.
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR t-cell therapy in refractory large b-cell lymphoma. N Engl J Med. 2017;377:2531-2544.
Pasquini MC, Hu ZH, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414-5424.
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45-56.
Subklewe M. Real-life CAR T-zellen in Deutschland. Presented at: Jahrestagung der Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO). October 9-11, 2020. Abstract V-129.
Subklewe M, et al. Hematotoxicity and infectious complications of CD19-CAR T-cell treated patients: real-world data from Munich (LMU). Presented at: Second European CAR T Cell Meeting, European Society for Blood and Marrow Transplantation (EBMT) and European Hematology Association (EHA). January 30-February 1, 2020; Sitges, Barcelona, Spain.
Rajeski K, Berger C, Jentzsch L, et al. Identification of predictive markers of severe and prolonged neutropenia after CD19-specific CAR T-cell treatment in patients with relapsed/refractory B-cell malignancies. Presented at: 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. December 5-8, 2020. Abstract 1446.
Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105:297-316.
YESCARTA® (axicabtagene ciloleucel) [prescribing information]. Kite Pharma, Inc. Approved 2017. Revised July 2020.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Marion Subklewe, MD

Professor for Cellular Immunotherapy
Associate Professor for Hematology
University Hospital of Munich
Munich, Bavaria, Germany

Disclosures

Disclosure: Marion Subklewe, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Celgene; Gilead; Janssen; Novartis; Pfizer; Seattle Genetics
Served as a speaker or a member of a speakers bureau for: Amgen; Celgene
Received grants for clinical research from: Amgen; Gilead; Miltenyi; Morphosys; Roche; Seattle Genetics

Faculty

Marie José Kersten, MD, PhD

Professor of Hematology
Amsterdam UMC and LYMMCARE (Lymphoma and Myeloma Center Amsterdam)
Amsterdam, The Netherlands

Disclosures

Disclosure: Marie José Kersten, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol Myers Squibb Company; Celgene; Gilead; Kite; Miltenyi; Novartis; Takeda
Served as a speaker or a member of a speakers bureau for: Bristol Myers Squibb Company; Celgene; Gilead; Kite; Novartis; Roche
Received grants for clinical research from: Gilead; Kite; Roche; Takeda

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Yoji Yamaguchi

Associate Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Yoji Yamaguchi has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

CAR T-Cell Therapy in Real Practice: Optimizing Referral and Treatment of Patients With NHL

Authors: Marion Subklewe, MD; Marie José Kersten, MD, PhD
CPD Released: 2/16/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 2/16/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology and oncology specialists.

The goal of this activity is to educate physicians how to identify and refer patients eligible to receive chimeric antigen receptor (CAR) T-cell therapy, as well as the management of these patients.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Differences between real-world outcomes and clinical trials when treating patients with CAR T-cell therapy
- Late side effects when treating patients with CAR T-cell therapy
- Identification and referral of patients eligible for CAR T-cell therapy
Demonstrate greater confidence in their ability to
- Manage patients who have been referred for CAR T-cell therapy

Disclosures

Moderator

Marion Subklewe, MD

Professor for Cellular Immunotherapy
Associate Professor for Hematology
University Hospital of Munich
Munich, Bavaria, Germany

Disclosures

Disclosure: Marion Subklewe, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Celgene; Gilead; Janssen; Novartis; Pfizer; Seattle Genetics
Served as a speaker or a member of a speakers bureau for: Amgen; Celgene
Received grants for clinical research from: Amgen; Gilead; Miltenyi; Morphosys; Roche; Seattle Genetics

Faculty

Marie José Kersten, MD, PhD

Professor of Hematology
Amsterdam UMC and LYMMCARE (Lymphoma and Myeloma Center Amsterdam)
Amsterdam, The Netherlands

Disclosures

Disclosure: Marie José Kersten, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol Myers Squibb Company; Celgene; Gilead; Kite; Miltenyi; Novartis; Takeda
Served as a speaker or a member of a speakers bureau for: Bristol Myers Squibb Company; Celgene; Gilead; Kite; Novartis; Roche
Received grants for clinical research from: Gilead; Kite; Roche; Takeda

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Yoji Yamaguchi

Associate Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Yoji Yamaguchi has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

CAR T-Cell Therapy in Real Practice: Optimizing Referral and Treatment of Patients With NHL

Authors: Marion Subklewe, MD; Marie José Kersten, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 2/16/2021

Valid for credit through: 2/16/2022, 11:59 PM EST

processing....

Commentaire d'expert en français

Ce commentaire fait partie d’une activité de formation plus vaste. Après la participation, prière de retourner à CAR T-Cell Therapy in Real Practice: Optimizing Referral and Treatment of Patients With NHL pour accéder à l’ensemble du contenu de formation relié.

« Return to: CAR T-Cell Therapy in Real Practice: Optimizing Referral and Treatment of Patients With NHL